Ion Beam Analysis and PD-MS As New Analytical Tools for Quality Control of Pharmaceuticals: Comparative Study from Fluphenazine in Solid Dosage Forms
- 1. Lebanese Atomic Energy CommissionsCNRS, Airport Road, PO Box 11-8281, Beirut, (Lebanon)
- 2. Institut de Physique Nucleaire de Lyon, Universite Lyon 1, CNRS/IN2P3, 4 rue E. Fermi 69622 Villeurbanne Cedex (France)
- 3. Institut de Physique Nucleaire, CNRS-IN2P3, 91406 Orsay (France)
Description
In order to evaluate the potential of accelerator based analytical techniques ((particle induced X-ray emission (PIXE), particle induced gamma-ray emission (PIGE), and particle desorption mass spectrometry (PD-MS)) for the analysis of commercial pharmaceutical products in their solid dosage form, the fluphenazine drug has been taken as a representative example. It is demonstrated that PIXE and PIGE are by far the best choice for quantification of the active ingredient (AI) (certification with 7% precision) from the reactions induced on its specific heteroatoms fluorine and sulfur using pellets made from original tablets. Since heteroatoms cannot be present in all types of drugs, the PD-MS technique, which makes easily the distinction between AI(s) and excipients, has been evaluated for the same material. It is shown that the quantification of AI is obtained via the detection of its protonated molecule. However, calibration curves have to be made from the secondary ion yield variations since matrix effects of various nature are characteristics of such mixtures of heterogeneous materials (including deposits from soluble components). From the analysis of solidablets, (either transformed into pellets and even as received), it is strongly suggested that the physical state of the grains in the mixture is a crucial parameter in the ion emission and accordingly for the calibration curves. As a result of our specific (but not optimized) conditions the resulting precision is <17% with an almost linear range extending from 0.04 to 7.87 mg of AI in a tablet made under the manufacturer conditions (the commercial drug product is labeled at 5 mg). Commercial pharmaceutical drugs contain one or more therapeutic. (author)
Availability note (English)
Available from DOI: 10.1021/ac101247dAdditional details
Identifiers
- DOI
- 10.1021/ac101247d;
Publishing Information
- Journal Title
- Analytical Chemistry (Washington)
- Journal Volume
- 82
- Journal Page Range
- p. 7309-7318
- ISSN
- 0003-2700
INIS
- Country of Publication
- United States
- Country of Input or Organization
- Lebanon
- INIS RN
- 50081831
- Subject category
- S46: INSTRUMENTATION RELATED TO NUCLEAR SCIENCE AND TECHNOLOGY; S75: CONDENSED MATTER PHYSICS, SUPERCONDUCTIVITY AND SUPERFLUIDITY;
- Descriptors DEI
- ACCELERATORS; ANALYTICAL SOLUTION; DRUGS; FLUORINE; GAMMA DETECTION; MASS; PARTICLE BEAMS; PELLETS; PIXE ANALYSIS; SOLIDS; SPECTROSCOPY; SULFUR; THERAPEUTIC USES
- Descriptors DEC
- BEAMS; CHEMICAL ANALYSIS; DETECTION; ELEMENTS; HALOGENS; MATHEMATICAL SOLUTIONS; NONDESTRUCTIVE ANALYSIS; NONMETALS; RADIATION DETECTION; USES; X-RAY EMISSION ANALYSIS
Optional Information
- Notes
- 9 figs.; 25 refs.; Copyright © 2010, American Chemical Society